Dynamic contrast-enhanced computed tomography as a potential biomarker in patients with metastatic colorectal cancer treated with regorafenib.
CONCLUSION: In this exploratory study, a significant decrease in most dynamic parameters suggests an overall treatment effect of regorafenib in tumor vasculature. DCE-CT may assist in an objective evaluation of these responses compared to RECIST. The anti-angiogenic changes could not be associated with treatment outcome in terms of PFS and OS, which might be due to the small cohort or a rather limited survival benefit in this pre-medicated treatment-refractory group of patients.
PMID: 30348001 [PubMed - as supplied by publisher]
Source: Acta Radiologica - Category: Radiology Authors: Andersen IR, Olesen R, Boysen AK, Jensen LH, Mortensen FV, Nielsen DT, Rasmussen F Tags: Acta Radiol Source Type: research
More News: Cancer | Cancer & Oncology | Colorectal Cancer | CT Scan | Liver | Perfusion | PET Scan | Radiology | Study | Urology & Nephrology